Renal impairment under triple therapy with boceprevir in German real-life: evidence for a pivotal role for peginterferon/ribavirin backbone, female gender and age elder than 50 ye…
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: Recently, renal impairment corresponding to renal insufficiency stage 3 has been reported in about 5% of patients treated for HCV genotype 1 infection with telaprevir or boceprevir (S Mauss et al., Hepatology 2014; 59:46 – 48). The present interim analysis of the NOVUS observational study was conducted to determine the frequency of stage 2 and stage 3 renal insufficiencies and to elucidate associated risk factors and mechanisms in patients (pts) undergoing boceprevir triple therapy in German real-life. Methods: From April 2012 until January 2014, 536 pts with HCV G1 infection were recruited in the on…
